其它产品项目整合

项目整合的本质是一项集合成方法学、反应工程学与过程分析技术于一体的系统工程。其核心逻辑可以概括为以下几点：源头优选：利用如N-硝胺化学等底层方法学突破，从分子层面颠覆传统高成本、高污染路线。过程强化：依托连续流技术，攻克有机金属试剂应用、光化学反应放大等“不可能”任务，实现高危工艺的本质安全。系统集成：整合“反应-淬灭-分离”全流程，利用微流控与在线分析技术，消除批次间的差异，实现药品制造的连续化与智能化。当前，中间体工艺研发正在经历从“经验驱动”向“数据驱动”的转变。AI辅助路线设计、自动化高通量筛选与连续制造平台的结合，将使得“分子结构与最优工艺路径”之间的映射关系逐渐清晰。未来的竞争优势，将属于那些能够将底层化学创新与先进工程技术进行无缝整合的研发体系。
备注: 根据相关法律法规, 本站点不显示有法律约束管制的产品, 如有遗漏, 请自行鉴别,或提交我们及时更新撤除.
如有产品相关项目调研推广服务, 请致函联系我们

客户展示

其它产品项目整合

Vigabatrin CAS Registry Number: 60643-86-9 氨己烯酸

CAS Name: 4-Amino-5-hexenoic acid
Additional Names: g-vinyl-g-aminobutyric acid; gamma-vinyl GABA; g-vinyl GABA; GVGTrademarks: Sabril (HMR)
Percent Composition: C 55.79%, H 8.58%, N 10.84%,...
Literature References: Irreversible inhibitor of g-aminobutyric acid transaminase, the enzyme responsible for the degradation of the neurotransmitter g-aminobutyric acid (GABA). Prepn: B. W. Metcalf, M. Jung, US 3960927 (1976 to Richardson-Merrell); and in vitro enzyme inactivation: B. Lippert et al., Eur. J. Biochem. 74, 441 (1977). Mechanism of action study: P. J. Schechter et al., Eur. J. Pharmacol. 45, 319 (1977). Anticonvulsant activity and toxicity studies: W. Löscher, Neuropharmacology 21, 803 (1982). HPLC determn in plasma and urine: J. A. Smithers et al., J. Chromatogr. 341, 232 (1985). The S(+)-enantiomer is the pharmacologically active form. Pharmacokinetics of enantiomers in humans: K. D. Haegele, P. J. Schechter, Clin. Pharmacol. Ther. 40, 581 (1986). Clinical studies in treatment resistant epilepsy: C. A. Tassinari et al., Arch. Neurol. 44, 907 (1987); T. R. Browne et al., Neurology 37, 184 (1987). Series of articles on clinical use in adult and childhood epilepsy: J. Child Neurol. 6, Suppl. 2, S3-S69 (1991). Reviews of early literature and mechanism of action: M. J. Iadarola, K. Gale, Mol. Cell. Biochem. 39, 305-330 (1981); of pharmacology and toxicology: E. J. Hammond, B. J. Wilder, Clin. Neuropharmacol. 8, 1-12 (1985). Review: S. M. Grant, R. C. Heel, Drugs 41, 889-926 (1991).

Eflornithine CAS Registry Number: 67037-37-0 依氟鸟氨酸

CAS Name: 2-(Difluoromethyl)-DL-ornithine
Additional Names: a-difluoromethylornithine; DFMOPercent Composition: C 39.56%, H 6.64%, F 20.86%, N 15.38%, O 17.57%
Literature References: Irreversible inhibitor of ornithine decarboxylase, an enzyme involved in polyamine biosynthesis. Prepn: B. W. Metcalf et al., J. Am. Chem. Soc. 100, 2551 (1978); P. Bey et al., J. Org. Chem. 44, 2732 (1979). Effect on polyamine biosynthesis in trypanosomes: C. J. Bacchi et al., Science 210, 332 (1980). Clinical pharmacokinetics: K. D. Haegele et al., Clin. Pharmacol. Ther. 30, 210 (1981). Reviews of clinical experience in Pneumocystis carinii pneumonia: J. Sahai, A. J. Berry, Pharmacotherapy 9, 29-33 (1989); in cancer chemotherapy: F. L. Meyskens, Jr., E. W. Gerner, Clin. Cancer Res. 5, 945-951 (1999); in trypanosomiasis: C. Burri, R. Brun, Parasitol. Res. 90, S49-S52 (2003). Review of topical use in hirsutism: J. A. Barman Balfour, K. McClellen, Am. J. Clin. Dermatol. 2, 197-201 (2001).

Mofegiline CAS Registry Number: 119386-96-8 莫非吉兰

CAS Name: (bE)-4-Fluoro-b-(fluoromethylene)benzenebutanamine
Additional Names: (E)-2-(fluoromethylene)-4-(p-fluorophenyl)butylamine; (E)-2-(4-fluorophenethyl)-3-fluoroallylamine
Percent Comp...
Literature References: Irreversible monoamine oxidase-B (MAO-B) inhibitor. Prepn: I. A. McDonald, M. G. Palfreyman, EP 295604 (1988 to Merrell Dow). GC-MS determn in plasma and urine: B. D. Dulery et al., J. Chromatogr. 571, 241 (1991). Pharmacokinetics: eidem et al., Arzneim.-Forsch. 43, 297 (1993). Metabolism: J. Dow et al., Drug Metab. Dispos. 22, 738 (1994). Clinical pharmacology: C. Hinze et al., J. Neural Transm. Suppl. 41, 371-375 (1994). Clinical evaluation in Parkinson's disease: V. V. Myllylä et al., Adv. Neurol. 60, 676 (1993).

Canertinib CAS Registry Number: 267243-28-7 卡奈替尼

CAS Name: N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl]-2-propenamide
Additional Names: N-[4-(3-chloro-4-fluorophenylamino)-7-(3-morpholin-4-ylpropoxy)quina...
Literature References: Irreversible pan-erbB tyrosine kinase inhibitor. Prepn: A. J. Bridges et al., WO 0031048; eidem, US 6344455 (2000, 2002 both to Warner-Lambert); J. B. Smaill et al., J. Med. Chem. 43, 1380 (2000). Clinical pharmacokinetics in patients with solid malignancies: E. Calvo et al., Clin. Cancer Res. 10, 7112 (2004); and tolerability in refractory cancer: J. Nemunaitis et al., ibid. 11, 3846 (2005). Review of pharmacology and mechanism of action: L. F. Allen et al., Semin. Oncol. 30, Suppl. 16, 65-78 (2003); of development and clinical experience: C. M. Galmarini, IDrugs 7, 58-63 (2004).

Resorcinol CAS Registry Number: 108-46-3 间苯二酚

CAS Name: 1,3-Benzenediol
Additional Names: m-dihydroxybenzene; resorcin
Percent Composition: C 65.45%, H 5.49%, O 29.06%
Literature References: Is at least 99.5% pure. Made by fusing m-benzenedisulfonic acid with excess NaOH. Review: J. Varagnat in Kirk-Othmer Encyclopedia of Chemical Technology vol. 13 (Wiley-Interscience, New York, 3rd ed., 1981) pp 39-69. Review of toxicology and risk assessment: B. S. Lynch et al., Regul. Toxicol. Pharmacol. 36, 198-210 (2002).

HHCB CAS Registry Number: 1222-05-5 1,3,4,6,7,8-六氢-4,6,6,7,8,8-六甲基环五-γ-2-苯并吡喃

CAS Name: 1,3,4,5,6,7,8-Hexahydro-4,6,6,7,8,8-hexamethylcyclopenta[g]-2-benzopyran
Additional Names: 6-oxa-1,1,2,3,3,8-hexamethyl-2,3,5,6,7,8-hexahydro-1H-benz[f]-indene
Trademarks: Galaxoli...
Literature References: Isochroman musk odorant; scent is primarily due to the (-)-(4S,7R) and (-)-(4S,7S) isomers. Prepn: L. G. Heeringa, M. G. J. Beets, GB 991146; eidem, US 3360530 (1965, 1967 both to International Flavors Fragrances). Prepn and olfactory characterization of enantiomers: G. Fráter et al., Helv. Chim. Acta 82, 1656 (1999). Synthesis of olfactorally active stereoisomers: A. Ciappa et al., Tetrahedron: Asymmetry 13, 2193 (2002). HPLC determn: W. Schüssler, L. Nitschke, Fresenius J. Anal. Chem. 361, 220 (1998). Subchronic toxicity study: A. M. Api, R. A. Ford, Toxicol. Lett. 111, 143 (1999).

Ipriflavone CAS Registry Number: 35212-22-7 依普黄酮

CAS Name: 7-(1-Methylethoxy)-3-phenyl-4H-1-benzopyran-4-one
Additional Names: 7-isopropoxy-3-phenyl-4H-1-benzopyran-4-one; 7-isopropoxy-3-phenylchromone; 7-isopropoxyisoflavoneTrademarks: Ipros...
Literature References: Isoflavone derivative with anti-anginal and anti-osteopenic activity. Prepn: L. Feuer et al., DE 2125245 (1971 to Chinoin), C.A. 76, 72407e (1972). Use as anabolic in animals: eidem, US 3833730; in humans; eidem, US 3949085 (1974, 1976 both to Chinoin). Cardiovascular properties in stable angina: V. Grubich et al., Lancet 1, 211 (1979). Cardiological effects in animals: L. Feuer et al., Arzneim.-Forsch. 31, 953 (1981). Metabolism and disposition in rats: K. Yoshida et al., Radioisotopes 34, 612, 618 (1985). Effect in rats on estrogen-stimulated calcitonin secretion: I. Yamazaki, Life Sci. 38, 757 (1986); I. Yamazaki, M. Kinoshita, ibid. 1535; on glucocorticoid-induced osteoporosis: I. Yamazaki et al., ibid. 951.

Coclaurine CAS Registry Number: 486-39-5 衡州乌药碱; 乌药碱

CAS Name: (1S)-1,2,3,4-Tetrahydro-1-[(4-hydroxyphenyl)methyl]-6-methoxy-7-isoquinolinol
Additional Names: 1-(p-hydroxybenzyl)-6-methoxy-7-hydroxy-1,2,3,4-tetrahydroisoquinoline; machiline
Pe...
Literature References: Isolated as the racemate from species of Machilus (Lauraceae) and Cocculus (Menispermaceae). First isoln from C. laurifolius D.C. believed to be of the d-form: Kondo, Kondo, J. Pharm. Soc. Jpn. No. 524, 876 (1925), C.A. 20, 6047 (1926); see also Johns et al., Aust. J. Chem. 20, 1729 (1967). Structure: Kondo, Kondo, J. Pharm. Soc. Jpn. 48, 1156 (1928); Tomita, Kusuda, ibid. 72, 280 (1952). Synthesis: Kratzl, Billek, Monatsh. Chem. 82, 568 (1951); Finkelstein, J. Am. Chem. Soc. 73, 550 (1951). Identity with machiline: Tomita et al., J. Pharm. Soc. Jpn. 83, 218 (1963), C.A. 59, 2874a (1963). Crystal structure and absolute configuration: Fridrichsons, Mathieson, Tetrahedron 24, 5785 (1968).

Thymol CAS Registry Number: 89-83-8 麝香草酚

CAS Name: 5-Methyl-2-(1-methylethyl)phenol
Additional Names: 5-methyl-2-isopropyl-1-phenol; 1-methyl-3-hydroxy-4-isopropylbenzene; 3-p-cymenol; 3-hydroxy-p-cymene; thyme camphor; m-thymol
Pe...
Literature References: Isolated by Neumann in 1719. Obtained from the essential oil of Thymus vulgaris L. and Monarda punctata L., Labiatae: Arppe, Ann. 58, 41 (1846); Meyer, Pharm. Ztg. 81, 192, 205 (1936). Also occurs in other volatile oils. Produced synthetically from p-cymene, piperitone, or m-cresol: Austerweil, GB 221227 (1923); Jennen, Verdroncken, Compt. Rend. 245, 183 (1957); Bottoms, US 2840616 (1958 to Natl. Cylinder Gas). Bactericidal activity: J. M. Schaffer, F. W. Tilley, J. Bacteriol. 14, 259 (1927). Mold elimination on surfaces: O. W. Richards, K. J. Hawley, J. Chem. Educ. 16, 6 (1939). In vitro antifungal activity: H. B. Myers, J. Am. Med. Assoc. 89, 1834 (1927). Effectiveness as antifungal preservative: M. Dersarkissian, M. Goodberry: Stud. Conserv. 25, 28 (1980). Use as clinical preservative: T. Z. Liu, Clin. Chem. 25, 336 (1979); T. Z. Liu et al., ibid. 27, 1144 (1981). Toxicity: P. M. Jenner et al., Food Cosmet. Toxicol. 2, 327 (1964).

Biotin l-Sulfoxide CAS Registry Number: 3376-83-8 (-)-生物素硫酸盐

CAS Name: [3aS-(3aa,4b,5b,6aa)]-Hexahydro-2-oxo-1H-thieno[3,4-d]imidazole-4-pentanoic acid 5-oxide
Additional Names: AN factor
Percent Composition: C 46.14%, H 6.20%, N 10.76%, O 24.59%, S 1...
Literature References: Isolated from Aspergillus niger culture filtrate where growth had taken place in the presence of pimelic acid; also from milk residue concentrates or by synthesis: Melville, J. Biol. Chem. 208, 495 (1954); Wright et al., J. Am. Chem. Soc. 76, 4163 (1954).